Canagliflozin: A novel SGLT2 inhibitor for type 2 diabetes mellitus

North American Journal of Medical Sciences

Volumn 6, Issue 3, 2014, Pages 107-113

  Kaushal, Shaveta ^a   Singh, Harmanjit ^b   Thangaraju, Pugazhenthan ^c   Singh, Jasbir ^d  

^a Production Engineering Department   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c Central Leprosy Teaching and Research Institute India   (India)

^d GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

Canaglifl ozin; Diabetes mellitus; H0062A1C; Inhibitors; SGLT2

Indexed keywords

CANAGLIFLOZIN; HEMOGLOBIN A1C;

AREA UNDER THE CURVE; BLOOD PRESSURE; CARDIOVASCULAR RISK; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; FUNGAL GENITAL INFECTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; HYPOTENSION; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORTHOSTATIC HYPOTENSION; POLLAKISURIA; POLYDIPSIA; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; URINARY TRACT INFECTION; WEIGHT REDUCTION;

EID: 84896038446     PISSN: 22501541     EISSN: 19472714     Source Type: Journal    
DOI: 10.4103/1947-2714.128471     Document Type: Review

References (62)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21.
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14.
3. IDF Diabetes Atlas Update 2012. (Accessed October 3, 2013, at http://www.idf.org/diabetesatlas/5e/Update2012).
4. Tahrani A, Bailey C, Del Prato S, Barnett AH. Management of type 2 diabetes: New and future developments in treatment. Lancet 2011;378:182-97.
5. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-46.
6. Ford ES. Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U.S.: Findings from the National Health and Nutrition Examination Survey, 1999-2008. Diabetes Care 2011;34:1337-43.
7. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012;35:S11-63.
8. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
9. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
10. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes (UKPDS 80). N Engl J Med 2008;359:1577-89.
11. Wagman AS, Nuss JM. Current therapies and emerging targets for the treatment of diabetes. Curr Pharm Des 2001;7:417-50.
12. Bailey CJ, Day C. SGLT2 inhibitors: Glucuretic treatment for type 2 diabetes. Br J Diabetes Vasc Dis 2010;10:193.
13. Wilding J. Thiazolidinediones, insulin resistance and obesity: Finding a balance. Int J Clin Pract 2006;60:1272-80.
14. Katsuno K, Fujimori Y, Ishikawa-Takemura Y, Isaji M. Long-term treatment with serglifl ozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur J Pharmacol 2009;618:98-104.
15. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
16. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: A nationwide study. Eur Heart J 2011;32:1900-8.
17. Gore MO, McGuire DK. Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: More support for cardiovascular outcome assessments. Eur Heart J 2011;32:1832-4.
18. DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(d,l-lactide-co-glycolide) microspheres produced an investigational long-acting onceweekly formulation for type-2 diabetes. Diabetes Technol Ther 2011;13:1145-54.
19. Zinman B, Schmidt WE, Moses A, Lund N, Gough S. Achieving a clinically relevant composite outcome of an HbA1C of <7% without weight gain or hypoglycemia in type 2 diabetes: A meta-analysis of the liraglutide clinical trial program. Diabetes Obes Metab 2012;14:77-82.
20. Byetta (exenatide injection) prescribing information. (Accessed October 4, 2013, at http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=751747da-7c1f-41ad-b1a6-a6d920f70599
21. Januvia (sitagliptin). (Accessed October 4, 2013, at http://www.drugs.com/monograph/januvia.html).
22. Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, et al. Safety and effi cacy of sitagliptin in patients with type 2 diabetes and chronic renal insuffi ciency. Diabetes Obes Metab 2008;10:545-55.
23. Mathers MC, Zarbock SD, Sutton EE. New and Future Medications for the Treatment of Type 2 Diabetes Mellitus. Am J Lifestyle Med 2013. [Published online before print]
24. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pfl ugers Arch 2004;447:510-8.
25. Patel AK, Fonseca V. Turning glucosuria into a therapy: Effi cacy and safety with SGLT2 inhibitors. Curr Diab Rep 2010;10:101-7.
26. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: Its importance in human glucose homeostasis. Diabetes Care 2001;24:382-91.
27. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007;261:32-43.
28. Song J. Dapagliflozin: An emerging treatment option for type 2 diabetes mellitus. Formulary 2011;46:412-31.
29. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia. Diabetes Obes Metab 2012;14:5-14.
30. Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971;28:101-9.
31. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodiumglucose transport: Role in diabetes mellitus and potential clinical implications. Kidney Int 2009;75:1272-7.
32. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, et al. Dapaglifl ozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-6.
33. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13:669-72.
34. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: A review. Diabetes Metab Res Rev 2005;21:31-8.
35. Stiles PG, Lusk G. On the action of phlorizin. Am J Physiol 1903;10:61-79.
36. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510-5.
37. Fujimori Y, Katsuno K, Ojima K, Nakashima I, Nakano S, Ishikawa-Takemura Y, et al. Serglifl ozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocininduced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009;609:148-54.
38. Nomura S, Sakamaki S, Hongu M, Kawanishi E, Koga Y, Sakamoto T, et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010;53:6355-60.
39. Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, et al. Effect of canaglifl ozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. Plos One 2012;7:e30555.
40. New Drugs at FDA. (Accessed October 4, 2013, at http://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/default.htm).
41. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin sompared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;353:837-53.
42. Inagaki N, Kondo K, Iwasaki T. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (SGLT2) improves glycemic control and reduces body weight in Japanese type 2 diabetes mellitus (T2DM). Diabetes 2011;60:abstract 0999-P.
43. Rosenstock J, Arbit D, Usiskin K, Capuano G, Canovatchel W. Canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2), improves glycemic control and lowers body weight in subjects with type 2 diabetes (T2D) on metformin. Orlando: American Diabetes Association; 2010, abstract 77.
44. Rosenstock J, Polidori D, Zhao Y, Sha S, Arbit D, Usiskin K, et al. Canagliflozin, an inhibitor of sodium glucose cotransporter 2 (SGLT2), improves glycemic control, lowers body weight and improves beta cell function in subjects with type 2 diabetes on back- ground metformin (T2D) on metformin. Diabetologia 2010;53:S1-556.
45. Yale JF, Bakris G, Xi L, Figueroa K, Wajs E, Usiskin K, et al. Canaglifl ozin, a SGLT2 inhibitor, improves glycemia and is well tolerated in type 2 diabetes mellitus subjects with moderate renal impairment. Abstracts. Can J Diabetes 2012;36:S24-76.
46. List JF, Whaley JM. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int Suppl 2011:120:S20-7.
47. Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, et al. Effi cacy and safety of canaglifl ozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013;15:463-73.
48. Holman RR, Paul SK, Bethel A, Neil HA, Matthews DR. Longterm follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359:1565-76.
49. Turnbull F, Abraira C, Anderson R, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-98.
50. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Metaanalysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
51. CANVAS. Canaglifl ozin Cardiovascula Assessment Study. (Accessed October 4, 2013, at http://clinicaltrials.gov/show/NCT01032629).
52. Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Effi cacy and safety of canaglifl ozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82.
53. Stenlof K, Cefalu WT, Tong C. Canaglifl ozin, a sodium glucose co-transporter 2 inhibitor, improves glycaemic control in subjects with type 2 diabetes inadequately controlled with diet and exercise (Abstract 760). Diabetologia 2012;55 Suppl 1:S312-3.
54. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Ecacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50.
55. Invokana (canaglifl ozin). Prescribing information. (Accessed October 4, 2013, at http: //www.invokanahcp.com/prescribing-information.pdf).
56. Invokana. (Accessed October 5, 2013, at http://www.drugs.com/invokana.html).
57. Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, Rusch S, et al. Pharmacokinetics and pharmacodynamics of canaglifl ozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 2013;53:601-10.
58. Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J, et al. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012;14:539-45.
59. Rosenstock J, Aggarwal N, Polidori D, Alba M, Usiskin K, Tong C, et al. Dose-ranging effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as add- on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-8.
60. Janssen Research and Development to Present Results from Five Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes. Janssen Research and Development, LLC, June 5, 2012. (Accessed October 4, 2013, at http://www.prnewswire.com/news-releases/janssenresearch).
61. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 Diabetes who do not have adequate glycemic control with metformin plus sulfonylurea- a 52-week randomized trial. Diabetes Care 2013;36:2508-15.
62. Calado J, Sznajer Y, Metzger D, Rita A, Hogan MC, Kattamis A, et al. Twenty-one additional cases of familial renal glucosuria: Absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol Dial Transplant 2008;23:3874-9.